Bamco Inc. NY boosted its stake in shares of Bio-Techne (NASDAQ:TECH) by 0.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,520,323 shares of the biotechnology company’s stock after purchasing an additional 3,348 shares during the period. Bio-Techne makes up about 1.1% of Bamco Inc. NY’s portfolio, making the stock its 23rd biggest position. Bamco Inc. NY owned approximately 4.06% of Bio-Techne worth $229,630,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in the business. Amalgamated Bank grew its position in Bio-Techne by 5.4% during the 4th quarter. Amalgamated Bank now owns 7,772 shares of the biotechnology company’s stock worth $1,007,000 after purchasing an additional 399 shares during the last quarter. Meadow Creek Investment Management LLC boosted its holdings in shares of Bio-Techne by 14.3% in the 4th quarter. Meadow Creek Investment Management LLC now owns 3,520 shares of the biotechnology company’s stock valued at $456,000 after acquiring an additional 440 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Bio-Techne by 17.5% in the 4th quarter. Jane Street Group LLC now owns 3,016 shares of the biotechnology company’s stock valued at $391,000 after acquiring an additional 449 shares during the last quarter. Advisor Group Inc. boosted its holdings in shares of Bio-Techne by 64.5% in the 4th quarter. Advisor Group Inc. now owns 1,288 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 505 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bio-Techne by 28.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,662 shares of the biotechnology company’s stock valued at $402,000 after purchasing an additional 593 shares during the period. 98.22% of the stock is currently owned by institutional investors.
Bio-Techne opened at $151.62 on Friday, according to MarketBeat. The company has a quick ratio of 4.30, a current ratio of 5.55 and a debt-to-equity ratio of 0.37. Bio-Techne has a 1 year low of $149.61 and a 1 year high of $151.80. The firm has a market capitalization of $5.61 billion, a P/E ratio of 44.33, a PEG ratio of 2.46 and a beta of 0.72.
Bio-Techne (NASDAQ:TECH) last posted its earnings results on Wednesday, May 2nd. The biotechnology company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.07. Bio-Techne had a net margin of 18.29% and a return on equity of 14.75%. The firm had revenue of $164.00 million during the quarter, compared to analysts’ expectations of $163.43 million. During the same period in the previous year, the business posted $0.97 EPS. The business’s revenue was up 13.9% compared to the same quarter last year. equities research analysts forecast that Bio-Techne will post 4.05 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 25th. Shareholders of record on Monday, May 14th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date of this dividend is Friday, May 11th. Bio-Techne’s dividend payout ratio is presently 37.43%.
Several research firms recently issued reports on TECH. Zacks Investment Research cut shares of Bio-Techne from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. Deutsche Bank decreased their target price on shares of Bio-Techne from $167.00 to $165.00 and set a “buy” rating for the company in a research note on Thursday, May 3rd. Leerink Swann set a $160.00 target price on shares of Bio-Techne and gave the company a “buy” rating in a research note on Thursday, May 3rd. ValuEngine upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, BidaskClub upgraded shares of Bio-Techne from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 16th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Bio-Techne currently has a consensus rating of “Buy” and a consensus target price of $150.83.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne (NASDAQ:TECH).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.